mecamylamine has been researched along with Chronic Illness in 5 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema." | 9.14 | Topical mecamylamine for diabetic macular edema. ( Campochiaro, PA; Channa, R; Cooke, JP; Do, DV; Hafiz, G; Heier, JS; Hsu, HH; Kengatharan, MK; Lit, ES; Lu, L; Monk, J; Nguyen, QD; Shah, SM; Syed, B; Zimmer-Galler, I, 2010) |
| " The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema." | 5.14 | Topical mecamylamine for diabetic macular edema. ( Campochiaro, PA; Channa, R; Cooke, JP; Do, DV; Hafiz, G; Heier, JS; Hsu, HH; Kengatharan, MK; Lit, ES; Lu, L; Monk, J; Nguyen, QD; Shah, SM; Syed, B; Zimmer-Galler, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papp, M | 1 |
| Gruca, P | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Litwa, E | 1 |
| Willner, P | 1 |
| Campochiaro, PA | 1 |
| Shah, SM | 1 |
| Hafiz, G | 1 |
| Heier, JS | 1 |
| Lit, ES | 1 |
| Zimmer-Galler, I | 1 |
| Channa, R | 1 |
| Nguyen, QD | 1 |
| Syed, B | 1 |
| Do, DV | 1 |
| Lu, L | 1 |
| Monk, J | 1 |
| Cooke, JP | 1 |
| Kengatharan, MK | 1 |
| Hsu, HH | 1 |
| Hentall, ID | 1 |
| Sagen, J | 1 |
| Hildebrand, BE | 1 |
| Svensson, TH | 1 |
| Hama, A | 1 |
| Menzaghi, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)[NCT00536692] | Phase 2 | 0 participants | Interventional | 2007-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mecamylamine and Chronic Illness
| Article | Year |
|---|---|
Topical mecamylamine for diabetic macular edema.
Topics: Administration, Topical; Adolescent; Adult; Aqueous Humor; Chronic Disease; Diabetic Retinopathy; En | 2010 |
4 other studies available for mecamylamine and Chronic Illness
| Article | Year |
|---|---|
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze | 2014 |
Spinal CSF from rats with painful peripheral neuropathy evokes catecholamine release from chromaffin cells in vitro.
Topics: Adrenal Medulla; Animals; Catecholamines; Cattle; Cells, Cultured; Cerebrospinal Fluid; Cerebrospina | 2000 |
Intraaccumbal mecamylamine infusion does not affect dopamine output in the nucleus accumbens of chronically nicotine-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chronic Disease; Dopamine; Extracellular | 2000 |
Antagonist of nicotinic acetylcholine receptors (nAChR) enhances formalin-induced nociception in rats: tonic role of nAChRs in the control of pain following injury.
Topics: Acute Disease; Animals; Chronic Disease; Male; Mecamylamine; Nicotinic Antagonists; Nociceptors; Pai | 2001 |